Ernexa Therapeutics Inc.
General ticker "ERNA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $50.2M (TTM average)
Ernexa Therapeutics Inc. does not follow the US Stock Market performance with the rate: -36.1%.
Estimated limits based on current volatility of 9.9%: low 10.63$, high 12.97$
Factors to consider:
- Total employees count: 9 as of 2022
- Earnings for 15 months up through Q1 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [24.12$, 145.08$]
- 2025-12-31 to 2026-12-31 estimated range: [7.50$, 43.47$]
Financial Metrics affecting the ERNA estimates:
- Negative: with PPE of -1.2 at the end of fiscal year the price was very high
- Negative: Operating cash flow per share per price, % of -14.11 <= 0.02
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Negative: Interest expense per share per price, % of 6.02 > 3.30
- Negative: Inventory ratio change, % of 73.64 > 0.80
- Negative: negative Industry operating cash flow (median)
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Negative: Industry earnings per price (median), % of -15.23 <= 0
Short-term ERNA quotes
Long-term ERNA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | $0.07MM | $0.58MM |
| Operating Expenses | $21.20MM | $16.26MM |
| Operating Income | $-21.14MM | $-15.67MM |
| Non-Operating Income | $-0.54MM | $-28.84MM |
| Interest Expense | $0.61MM | $6.75MM |
| R&D Expense | $5.92MM | $4.60MM |
| Income(Loss) | $-21.67MM | $-44.51MM |
| Taxes | $-0.00MM | $0.03MM |
| Profit(Loss)* | $-21.73MM | $-44.54MM |
| Stockholders Equity | $2.23MM | $1.70MM |
| Assets | $49.13MM | $5.27MM |
| Operating Cash Flow | $-20.41MM | $-15.84MM |
| Capital expenditure | $0.02MM | $0.37MM |
| Investing Cash Flow | $-0.02MM | $-0.36MM |
| Financing Cash Flow | $16.56MM | $6.26MM |
| Earnings Per Share** | $-102.22 | $-39.21 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.